Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.
Barry Goy, MD
Advertisement
Articles by Barry Goy, MD
Advertisement
Latest Updated Articles
Benefits, Risks With EBRT Plus SADT in Intermediate-Risk Prostate CancerPublished: February 14th 2025 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
An NP’s Perspective: Supporting Derm Toxicities in Breast Cancer as a Team
2
Managing Acute and Late Adverse Effects of Breast Cancer Radiation
3
NGS Streamlines Biomarker Testing in Solid Tumors
4
Solo Sevabertinib Shows Durable Activity in HER2+ NSCLC
5
